{
    "clinical_study": {
        "@rank": "90780", 
        "arm_group": [
            {
                "arm_group_label": "GDC-0032 Capsule", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "GDC-0032 Tablet", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This 2-part study will assess the effect of formulation and food on the pharmacokinetics of\n      GDC-0032 in healthy volunteers. Part 1 is an open-label, 3-period, 6-sequence study, and\n      Part 2 is an open-label 2-period crossover study. Subjects will receive single doses of\n      GDC-0032 capsule or tablet formulation, in the fasted or fed state."
        }, 
        "brief_title": "A Study of the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females of non-childbearing potential, between 18 and 55 years of age,\n             inclusive; females will meet the following criteria: they will be non-pregnant,\n             non-lactating, and either postmenopausal for at least 1 year or surgically sterile\n             for at least 90 days.\n\n          -  Body mass index (BMI) 18.5 to 32 kg/m2, inclusive\n\n          -  In good health, determined by no clinically significant findings from medical\n             history, 12-lead ECG, vital signs and clinical laboratory evaluations\n\n          -  Negative test for selected drugs of abuse at Screening (does not include alcohol) and\n             at each Check-in (Day -1; does include alcohol)\n\n          -  Negative hepatitis panel (including HBsAg and anti-HCV) and negative HIV antibody\n             screens\n\n          -  Males will either be sterile or agree to use approved methods of contraception as\n             defined by protocol from Period 1 Check-in (Period 1, Day -1) until 90 days following\n             the last dose of study drug\n\n        Exclusion Criteria:\n\n          -  Significant history or clinical manifestation of any metabolic, allergic,\n             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,\n             gastrointestinal, neurological, or psychiatric disorder (as determined by the\n             Investigator)\n\n          -  History of significant hypersensitivity, intolerance, or allergy to any drug\n             compound, food, or other substance, unless approved by the Investigator\n\n          -  History of stomach or intestinal surgery or resection that would potentially alter\n             absorption and/or excretion of orally administered drugs, except for appendectomy,\n             hernia repair, and/or cholecystectomy\n\n          -  History of alcoholism or drug addiction within 1 year prior to Period 1 Check-in\n             (Period 1, Day -1)\n\n          -  Clinically significant history of liver disease, including viral or other hepatitis,\n             current alcohol abuse, or cirrhosis\n\n          -  History of Type 1 or 2 diabetes mellitus and/or elevated fasting glucose (>120 mg/dL)\n             at baseline (as confirmed by repeat)\n\n          -  History of Gilbert's Syndrome\n\n          -  Evidence of malabsorption syndrome or other condition that would interfere with\n             enteral absorption\n\n          -  Inability or unwillingness to swallow pills or consume high-fat breakfast\n\n          -  Use of any tobacco- or nicotine-containing products  within 6 months prior to Period\n             1 Check-in (Period 1, Day -1) and during the entire study\n\n          -  Participation in any other investigational study drug trial in which receipt of an\n             investigational study drug occurred within 5 half-lives or 30 days, whichever is\n             longer, prior to Period 1 Check-in (Period 1, Day -1) and during the entire study\n             duration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980953", 
            "org_study_id": "GP28619"
        }, 
        "intervention": [
            {
                "arm_group_label": "GDC-0032 Capsule", 
                "description": "Capsule formulation, single doses", 
                "intervention_name": "GDC-0032", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "GDC-0032 Tablet", 
                "description": "Tablet formulation, single doses", 
                "intervention_name": "GDC-0032", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-Label Study to Evaluate the Effect of Particle Size, Formulation, and Food on the Pharmacokinetics of GDC-0032 in Healthy Subjects", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GP28619 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 192 hours post-dose"
            }, 
            {
                "measure": "Maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 192 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980953"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to maximum plasma concentration (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 192 hours post-dose"
            }, 
            {
                "measure": "Apparent terminal elimination rate constant", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 192 hours post-dose"
            }, 
            {
                "measure": "Apparent terminal elimination constant (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 192 hours post-dose"
            }, 
            {
                "measure": "Apparent total clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 192 hours post-dose"
            }, 
            {
                "measure": "Apparent volume of distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 192 hours post-dose"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 15 weeks"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}